Most cases (62/82 [75.6%]) carried mutations in MPN driver genes, mainly involving JAK2 (46/82 [56.1%]), while 20/82 (24.4%) cases were TN; a subset of patients underwent further investigation, which allowed the identification of variants affecting TET2, ASXL1, SRSF2, and RUNX1. This evidence concerns the gene ASXL1 and myeloproliferative neoplasm.